Format

Send to:

Choose Destination
See comment in PubMed Commons below
Mol Oncol. 2012 Apr;6(2):260-6. doi: 10.1016/j.molonc.2012.02.006. Epub 2012 Mar 6.

Paying for personalized care: cancer biomarkers and comparative effectiveness.

Author information

  • 1Department of Pharmacy, University of Washington, Seattle, WA 98195-7630, USA.

Abstract

Genomic-based diagnostics can play a key role in creating a more efficient healthcare system by directing patients toward beneficial therapies and away from therapies that pose substantial risk or are unlikely to improve outcomes for the patient. We outline how the value provided by diagnostics is closely linked to a range of factors including magnitude of health outcome improvement, avoiding adverse effect, diagnostic parameters, process of care, resource utilization, and costs. Comparative effectiveness approaches to evidence generation, including health outcome measurements, quality of life, economic analyses, decision modeling, and pragmatic clinical trials, can be used to provide stakeholders with a range of information to inform treatment, guidelines, coverage, and reimbursement decisions. Evidence of comparative effectiveness can also help support value-based reimbursement of cancer biomarkers and treatment strategies as means of paying for personalized medicine.

Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

PMID:
22429896
[PubMed - indexed for MEDLINE]
PMCID:
PMC3593045
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk